These studies have led to the guideline crafters of the Obesity Medicine Association (OMA) Clinical Practice Statement 2023 to express concern for the cardiovascular safety risks with the use of exogenous insulin or sulfonylureas (73). The gene discussed is INS; the disease is obesity disorder.